Movers and SHAKERS
Dyadic International Inc. (DYAI)
Step Closer to Generating Human-like Proteins with C1 Platform
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system. The company’s partnership portfolio with pharmaceutical and institutions includes the Zapi Project, Israel Institute for Biological Research, Mitsubishi Tanabe Pharma, Sanofi-Aventis covering the production of a diverse range of biologics, such as monoclonal antibodies, bispecific and Fc-fusion proteins. Dyadic also established a sub-licensing agreement with an Australian based drug development and contract manufacturing firm, Luina Bio, to utilize C1 platform for the development and commercialization of biological products to prevent and treat animal diseases. Company’s C1 bioenergy business was sold to Dupond Industrial Biosciences (DuPont) for $75 mm in 2015 granting the company the right to use C1 platform in biopharma applications.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for the price target, fundamental analysis, and rating.
A building block for human glycan is produced by the C1 platform. Dyadic’s research partner VTT Technical Research Centre of Finland (VTT) presented data showing expression of the building block (G0 glycan) of human-like glycoproteins (at 94% relative expression). We think this is a key milestone for the company to validate the C1 platform in bioproduction.
Expressing human-like proteins is insight. Glycoproteins, such as monoclonal antibodies, are proteins that have sugars (glycans) attached to them. The majority (over 50%) of the biologics, sales of which are expected to grow to 300 billion by 2022, are glycoproteins. Glycoengineering is crucial in drug development, as glycans have marked effects on stability, activity, antigenicity, and...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.